Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Research Paper | Synapse

April 17, 2021Open Access

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

CSChad J. SwansonProthena (United States)YZYong ZhangEisai (Japan)SDShobha DhaddaNutrasource

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Clinical Trials.gov NCT01767311 .

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Swanson et al. (Sat,) studied this question.

synapsesocial.com/papers/69d74ebff07a12db70b8a964 https://doi.org/https://doi.org/10.1186/s13195-021-00813-8

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Revising the definition of Alzheimer's disease: a new lexicon2010 · 1,853 citations
2Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease2010 · 85 citations
3The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation2001 · 1,210 citations
4Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease2005 · 551 citations
5A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease2017 · 570 citations